Olivier Collard
Overview
Explore the profile of Olivier Collard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Duffaud F, Italiano A, Bompas E, Rios M, Penel N, Mir O, et al.
Eur J Cancer
. 2021 Apr;
150:108-118.
PMID: 33895682
Background: This multi-cohort trial explored the efficacy and safety of regorafenib for patients with advanced sarcomas of bone origin; this report details the cohort of patients with metastatic or locally...
12.
Bouleftour W, Muron T, Guillot A, Tinquaut F, Rivoirard R, Jacquin J, et al.
Support Care Cancer
. 2021 Jan;
29(8):4257-4267.
PMID: 33409726
Purpose: The use of oral cancer drugs (OAD) has increased over the last two decades. The objective of this study was to measure the impact of a nurse-led telephone follow-up...
13.
Desage A, Bouleftour W, Rivoirard R, Magne N, Collard O, Fournel P, et al.
Am J Clin Oncol
. 2020 Dec;
44(3):109-113.
PMID: 33350679
Introduction: Immune checkpoint inhibitors (ICIs) have become part of cancer treatments. Their main side effects are immune-related adverse events (irAEs). So far, there has been no recommendation regarding routine vaccinations...
14.
Blanc-Durand F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, Floquet A, Meriaux E, et al.
Gynecol Oncol
. 2020 Jul;
159(1):129-135.
PMID: 32723678
Purpose: Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is a rare and rapidly lethal disease affecting young women. Cytoreductive surgery associated with chemotherapy followed by a high...
15.
Marec-Berard P, Laurence V, Occean B, Ray-Coquard I, Linassier C, Corradini N, et al.
J Adolesc Young Adult Oncol
. 2019 Nov;
9(2):172-182.
PMID: 31702419
The French standard chemotherapy for osteosarcoma combines high-dose methotrexate (HDM) and etoposide-ifosfamide (EI) in children and adolescents, and API-AI (doxorubicin-cisplatin-ifosfamide) in adults. We herein present the results of M-EI and...
16.
Varnier R, Le Saux O, Chabaud S, Garin G, Sohier E, Wang Q, et al.
Eur J Cancer
. 2019 Jul;
118:156-165.
PMID: 31351267
Objectives: The objectives of this study were to identify actionable genomic alterations in the gynaecological subpopulation of the ProfiLER programme and to report clinical efficacy of recommended targeted treatment (RTT)....
17.
Piperno-Neumann S, Ray-Coquard I, Occean B, Laurence V, Cupissol D, Perrin C, et al.
Int J Cancer
. 2019 Jun;
146(2):413-423.
PMID: 31246277
In the OS2006 study, patients younger than 18 years were treated with a methotrexate-based regimen (MTX), patients older than 25 years with a doxorubicin-cisplatin-ifosfamide-based regimen (API-AI), whereas patients aged 18-25 ...
18.
Mery B, Moriceau G, Rivoirard R, Collard O
Rev Prat
. 2018 Dec;
66(7):e298.
PMID: 30512313
No abstract available.
19.
Mery B, Moriceau G, Rivoirard R, Collard O
Rev Prat
. 2018 Dec;
66(7):e291-e297.
PMID: 30512312
No abstract available.
20.
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, et al.
Lancet Oncol
. 2018 Nov;
20(1):120-133.
PMID: 30477937
Background: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients...